Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Epilepsy in Down Syndrome, A Highly Prevalent Comorbidity

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Giménez, Sandra|||0000-0001-8031-2319
  • Fortea, Juan|||0000-0002-1340-638X
Individuals with Down syndrome (DS) have an increased risk for epilepsy during the whole lifespan, but especially after age 40 years. The increase in the number of individuals with DS living into late middle age due to improved health care is resulting in an increase in epilepsy prevalence in this population. However, these epileptic seizures are probably underdiagnosed and inadequately treated. This late onset epilepsy is linked to the development of symptomatic Alzheimer's disease (AD), which is the main comorbidity in adults with DS with a cumulative incidence of more than 90% of adults by the seventh decade. More than 50% of patients with DS and AD dementia will most likely develop epilepsy, which in this context has a specific clinical presentation in the form of generalized myoclonic epilepsy. This epilepsy, named late onset myoclonic epilepsy (LOMEDS) affects the quality of life, might be associated with worse cognitive and functional outcomes in patients with AD dementia and has an impact on mortality. This review aims to summarize the current knowledge about the clinical and electrophysiological characteristics, diagnosis and treatment of epileptic seizures in the DS population, with a special emphasis on LOMEDS. Raised awareness and a better understanding of epilepsy in DS from families, caregivers and clinicians could enable earlier diagnoses and better treatments for individuals with DS.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Sleep disorders in adults with down syndrome

  • Giménez, Sandra|||0000-0001-8031-2319
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Blessing, Esther
  • Osorio, Ricardo M.
  • Fortea, Juan|||0000-0002-1340-638X
Sleep disorders, despite being very frequent in adults with Down syndrome (DS), are often overlooked due to a lack of awareness by families and physicians and the absence of specific clinical sleep guidelines. Untreated sleep disorders have a negative impact on physical and mental health, behavior, and cognitive performance. Growing evidence suggests that sleep disruption may also accelerate the progression to symptomatic Alzheimer's disease (AD) in this population. It is therefore imperative to have a better understanding of the sleep disorders associated with DS in order to treat them, and in doing so, improve cognition and quality of life, and prevent related comorbidities. This paper reviews the current knowledge of the main sleep disorders in adults with DS, including evaluation and management. It highlights the existing gaps in knowledge and discusses future directions to achieve earlier diagnosis and better treatment of sleep disorders most frequently found in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

The clinical and neuropathological features of sporadic (Late-onset) and genetic forms of alzheimer's disease

  • Rujeedawa, Tanzil|||0000-0002-7089-1684
  • Carrillo Félez, Eva
  • Clare, Isabel C.H.|||0000-0002-5385-008X
  • Fortea, Juan|||0000-0002-1340-638X
  • Strydom, Andre
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Coppus, Antonia
  • Levin, Johannes|||0000-0001-5092-4306
  • Zaman, Shahid
The purpose of this review is to compare and highlight the clinical and pathological aspects of genetic versus acquired Alzheimer's disease: Down syndrome-associated Alzheimer's disease in (DSAD) and Autosomal Dominant Alzheimer's disease (ADAD) are compared with the late-onset form of the disease (LOAD). DSAD and ADAD present in a younger population and are more likely to manifest with non-amnestic (such as dysexecutive function features) in the prodromal phase or neurological features (such as seizures and paralysis) especially in ADAD. The very large variety of mutations associated with ADAD explains the wider range of phenotypes. In the LOAD, age-associated comorbidities explain many of the phenotypic differences.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications

  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Olmedo-Saura, Gonzalo|||0000-0003-4864-5548
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
Epilepsy and Alzheimer's disease (AD) incidence increases with age. There are recip-rocal relationships between epilepsy and AD. Epilepsy is a risk factor for AD and, in turn, AD is an independent risk factor for developing epilepsy in old age, and abnormal AD biomarkers in PET and/or CSF are frequently found in late-onset epilepsies of unknown etiology. Accordingly, epilepsy and AD share pathophysiological processes, including neuronal hyperexcitability and an early excitatory-inhibitory dysregulation, leading to dysfunction in the inhibitory GABAergic and excitatory glutamatergic systems. Moreover, both β-amyloid and tau protein aggregates, the anato-mopathological hallmarks of AD, have proepileptic effects. Finally, these aggregates have been found in the resection material of refractory temporal lobe epilepsies, suggesting that epilepsy leads to amyloid and tau aggregates. Some epileptic syndromes, such as medial temporal lobe epilepsy, share structural and functional neuroimaging findings with AD, leading to overlapping symptomatology, such as episodic memory deficits and toxic synergistic effects. In this respect, the existence of epilepti-form activity and electroclinical seizures in AD appears to accelerate the progression of cognitive decline, and the presence of cognitive decline is much more prevalent in epileptic patients than in elderly patients without epilepsy. Notwithstanding their clinical significance, the diagnosis of clinical seizures in AD is a challenge. Most are focal and manifest with an altered level of consciousness without motor symptoms, and are often interpreted as cognitive fluctuations. Finally, despite the frequent association of epilepsy and AD dementia, there is a lack of clinical trials to guide the use of antiseizure medications (ASMs). There is also a potential role for ASMs to be used as disease-modifying drugs in AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Alzheimer's disease research progress in the Mediterranean region, The Alzheimer's Association International Conference Satellite Symposium

  • Sexton, Claire|||0000-0002-3846-2986
  • Solis, Michele
  • Aharon-Peretz, Judith
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Apostolova, Liana G.
  • Bayen, Eléonore
  • Birkenhager, Betty
  • Cappa, Stefano
  • Constantinidou, Fofi|||0000-0002-7928-8363
  • Fortea, Juan|||0000-0002-1340-638X
  • Gerritsen, Debby L.
  • Hassanin, Hany I.
  • Ibáñez, Agustín|||0000-0001-6758-5101
  • Ioannidis, Panagiotis|||0000-0003-0254-6624
  • Karageorgiou, Elissaios
  • Korczyn, Amos
  • Leroi, Iracema
  • Lichtwarck, Bjorn
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Lynch, Chris
  • Mecocci, Patrizia|||0000-0003-0729-5246
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Papatriantafyllou, John
  • Papegeorgiou, Sokratis
  • Politis, Antonis
  • Raman, Rema
  • Ritchie, Karen
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Sano, Mary
  • Scarmeas, Nikolas
  • Spiru, Luiza
  • Stathi, Afroditi
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Yener, Gorsev|||0000-0002-7756-4387
  • Zaganas, Ioannis|||0000-0002-0774-5772
  • Zygouris, Stelios|||0000-0001-9384-1826
  • Carrillo, Maria|||0000-0003-3057-2387
As research and services in the Mediterranean region continue to increase, so do opportunities for global collaboration. To support such collaborations, the Alzheimer's Association was due to hold its seventh Alzheimer's Association International Conference Satellite Symposium in Athens, Greece in 2021. Due to the COVID-19 pandemic, the meeting was held virtually, which enabled attendees from around the world to hear about research efforts in Greece and the surrounding Mediterranean countries. Research updates spanned understanding the biology of, treatments for, and care of people with Alzheimer's disease (AD_ and other dementias. Researchers in the Mediterranean region have outlined the local epidemiology of AD and dementia, and have identified regional populations that may expedite genetic studies. Development of biomarkers is expected to aid early and accurate diagnosis. Numerous efforts have been made to develop culturally specific interventions to both reduce risk of dementia, and to improve quality of life for people living with dementia.